Ifn-Gamma(+)Cd4(+)T Cell-Driven Prophylactic Potential Of Recombinant Ldbpk_252400 Hypothetical Protein Of Leishmania Donovani Against Visceral Leishmaniasis

Visceral leishmaniasis (VL) is a potentially fatal parasitic disease causing high morbidity and mortality in developing countries. Vaccination is considered the most effective and powerful tool for blocking transmission and control of diseases. However, no vaccine is available so far in the market for humans. In the present study, we characterized the hypothetical protein LDBPK_252400 of Leishmania donovani (LdHyP) and explored its prophylactic behavior as a potential vaccine candidate against VL. We found reduced hepato-splenomegaly along with more than 50% parasite reduction in spleen and liver after vaccination in mice. Protection in vaccinated mice after the antigen challenge correlated with the stimulation of antigen specific IFN-gamma expressing CD4(+)T cell (similar to 4.6 fold) and CD8(+)T cells (similar to 2.1 fold) in vaccinated mice in compared to infected mice, even after 2-3 months of immunization. Importantly, antigen-mediated humoral immunity correlated with high antigen specific IgG2/IgG1 responses in vaccinated mice. In vitro re-stimulation of splenocytes with LdHyP enhances the expression of TNF-alpha, IFN-gamma, IL-12 and IL-10 cytokines along with lower IL-4 cytokine and IL-10/IFN-gamma ratio in vaccinated mice. Importantly, we observed similar to 3.5 fold high NO production through activated macrophages validates antigen mediated cellular immunity induction, which is critical in controlling infection progression. These findings suggest that immunization with LdHyP mount a very robust immunity (from IL-10 towards TFN-gamma mediated responses) against L. donovani infection and could be explored further as a putative vaccine candidate against VL.